On June 20, 2025, analyst Raghuram Selvaraju from HC Wainwright & Co. announced updates regarding Cocrystal Pharma (COCP, Financial). The firm maintained its 'Buy' rating for the company's stock, signaling continuous confidence in the company's performance.
The price target for Cocrystal Pharma (COCP, Financial) has been adjusted from $7.00 to $6.00. This adjustment reflects a 14.29% decrease in the price target. Despite this target reduction, the 'Buy' rating remains unchanged, showing a positive long-term outlook from the analyst.
Cocrystal Pharma (COCP, Financial) continues to be evaluated under a 'Buy' rating, highlighting potential growth opportunities in the biopharmaceutical sector. Investors are advised to consider the new price target of $6.00 while making investment decisions.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 3 analysts, the average target price for Cocrystal Pharma Inc (COCP, Financial) is $8.33 with a high estimate of $10.00 and a low estimate of $7.00. The average target implies an upside of 437.63% from the current price of $1.55. More detailed estimate data can be found on the Cocrystal Pharma Inc (COCP) Forecast page.
Based on the consensus recommendation from 2 brokerage firms, Cocrystal Pharma Inc's (COCP, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
